Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
-
Market Cap
23.72M
Enterprise Value
-44.47M
Income
-14.83M
Sales
0.00M
Book/sh
5.27
Cash/sh
5.44
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
12
IPO
Mar 02, 2022
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.36
P/C
0.35
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
67.79
Current Ratio
67.79
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-1.22
EPS next Y
-2.23
EPS next Q
-0.44
EPS this Y
-15.48%
EPS next Y
-19.84%
EPS next 5Y
-7.39%
EPS past 3/5Y
-16.41% -9.71%
Sales past 3/5Y
- -
EPS Y/Y TTM
96.25%
Sales Y/Y TTM
-100.00%
EPS Q/Q
75.06%
Sales Q/Q
-
Insider Own
11.60%
Insider Trans
0.00%
Inst Own
4.64%
Inst Trans
-2.56%
ROA
-19.89%
ROE
-20.72%
ROIC
-22.42%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-19.42%
SMA50
-34.08%
SMA200
-49.22%
Trades
Shs Outstand
12.54M
Shs Float
11.09M
52W High
14.91 -87.32%
52W Low
1.90 -0.53%
Volatility
7.99% 7.38%
ATR (14)
0.16
RSI (14)
20.86
Beta
2.87
Rel Volume
1.40
Avg Volume
85.05K
Volume
5,944
Perf Week
-5.97%
Perf Month
-31.52%
Perf Quarter
-45.06%
Perf Half Y
-48.92%
Perf YTD
-82.40%
Perf Year
-81.43%
Perf 3Y
-98.25%
Perf 5Y
-
Perf 10Y
-
Prev Close
1.93
Price
1.89
Change %
-2.07%
Consensus
Strong Buy
Avg. Price Target
$18.61
Implied Upside
+884.7%
Analysts1incl. previous ratings
Rating Distribution1 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jun 08, 2026Initiated
AAlliance Global Partners
Buy$18+852.4%
Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.
PresidentMr. Joel Bradley Latham
CFOMr. Joseph Swan
Chief Medical OfficerDr. Luigi M. Barbato M.D.
Chief Technology OfficerMr. Lekhram Changoer M.Sc.
Chief Scientific OfficerDr. Mark Bleackley Ph.D.